PDCD1 and neoplasm: In particular, the combination of anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) has shown positive results in tumor treatment and significant enhancement in patients with metastatic melanoma [37], advanced RCC [38], and metastatic CRC [16, 39].